We established a strategic collaboration with Sosei Heptares in 2016 to discover, develop and commercialise novel antibody therapeutics targeting a number of G-protein-coupled receptors (GPCRs) with an initial focus on immuno-oncology.
Under the agreement, Sosei Heptares, the wholly-owned subsidiary of Sosei Group Corporation, will apply its StaR® platform to create stable antigens based on multiple GPCR targets that we select in partnership. Our Kymab teams will then use our human antibody discovery platforms to generate antibodies in response to immunisation with these antigens.
Our proprietary platforms will assure the highest probability of finding the best-in-class antibodies with highly attractive drug properties. We will take forward promising leads using the complementary skills, resources and development capabilities of the two companies in order to bring innovative products into the clinic.